LTG 305
Alternative Names: LTG-305Latest Information Update: 21 Aug 2024
Price :
$50 *
At a glance
- Originator Latigo Biotherapeutics
- Class Non-opioid analgesics; Small molecules
- Mechanism of Action Nav1.8 voltage-gated sodium channel inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Pain
Most Recent Events
- 21 Aug 2024 Preclinical trials in Pain in USA (PO) prior to August 2024 (Latigo Biotherapeutics pipeline, August 2024)
- 16 Aug 2024 Phase-I clinical trials in Pain (In volunteers) in USA (PO) (NCT06554574)
- 16 Aug 2024 Latigo Biotherapeutics plans a phase I safety and pharmacokinetics trial in healthy subjects in New Zealand (PO) (NCT06554574)